Navigation Links
Biomoda, Inc. Retains MicroCap Management, LLC as its Lead Corporate Communications and Broker Relations Firm.
Date:11/26/2007

ALBUQUERQUE, N.M., Nov. 26 /PRNewswire-FirstCall/ -- Biomoda, Inc. (OTC Bulletin Board: BMOD) (http://www.biomoda.com), maker of early-detection cancer diagnostic tests, has approved MicroCap Management as the front-runner of its full media campaign. MicroCap Management has created a strategic media plan that will provide a launch pad for present and future business driven by the progressive vision of Biomoda's Senior Executive Officers.

John Cousins, President of Biomoda announced, "MicroCap has the tools and connections to spread the word to the wider investment community about Biomoda and its potential." Alan Siegel, Managing Director of MicroCap Management, LLC stated: "We are thrilled to have Biomoda on board, and we're extremely enthusiastic about the future of this program."

MicroCap Management, LLC, headquartered in Orlando, Florida, is a Corporate Communications and Broker Relations firm that utilizes business-to-business marketing strategies and extensive relationships with major investment web portals to promote growth for publicly traded companies. Its Managing Directors possess 30+ years experience in marketing and advertising for OTC and Fortune 500 companies, and its highly trained Broker Relations staff has established relationships with broker/dealers nationwide, thereby providing maximum worldwide exposure to broker/dealers, investment bankers, wholesale and retail traders, as well as hedge fund managers and the global investment community.

MicroCap Management has its hands on the pulse of Wall Street, generating exposure and driving liquidity through its free Lead Generator Program and Broker Relations Campaigns; thereby creating a niche that traditional IR and PR firms haven't tapped.

MicroCap Management's core philosophy is to allow its corporate clients to focus on core business while managing its corporate communications and broker relations, and in doing so has frequently taken micro cap companies that were once acorns to a market penetration level of mature oak trees. As a side benefit, these strategies often assist in building the consumer markets as well, which in turn can contribute to increased shareholder equity.

Additionally, MicroCap Management's programs help companies meet pre-requisite criteria to qualify for listing on premier exchanges such as NASDAQ, AMEX and NYSE.

Biomoda's patented technology, a non-invasive cytology based assay, is designed for cancer screening of large populations at a reasonable cost. Current diagnostic methods for lung cancer, including CT scans and X-rays, often detect the disease only at more advanced stages and are relatively expensive.


'/>"/>
SOURCE Biomoda, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
2. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
3. Vical Names Andrew de Guttadauro Vice President, Corporate Development
4. Signalife Provides Corporate Update
5. Biomira Announces Plan to Reincorporate in the United States
6. Pressure BioSciences, Inc. Provides Corporate Update
7. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
8. Clinsys Clinical Research, Inc. Announces Relocation of Corporate Headquarters
9. ProMed Alliance International Inc. Corporate Name and Trading Symbol Expected to Change Effective Tomorrow
10. MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated
11. New Corporate Website Launched - Focus on Life Scientists, Flow Cytometrists, & Clinicians
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ... granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator ... osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular STAT3 ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... (ADC) therapeutics, today confirmed licensing rights that give it exclusive global access ... developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, an ...
(Date:10/10/2017)... ... , ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. ... The event entitled “Stem Cells and Their Regenerative Powers,” was held on August ... MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017 SomaGenics ... from the NIH to develop RealSeq®-SC (Single Cell), expected ... for profiling small RNAs (including microRNAs) from single cells ... Program highlights the need to accelerate development of approaches ... "New techniques for measuring levels ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
(Date:3/30/2017)... , March 30, 2017  On April 6-7, 2017, ... the Genome hackathon at Microsoft,s headquarters in ... competition will focus on developing health and wellness apps ... Hack the Genome is the first hackathon ... The world,s largest companies in the genomics, tech and ...
Breaking Biology News(10 mins):